Featured content in this Issue:

• A Look at Potential Mutual Recognition of FDA Approval for Psychedelics Via the UK MHRA’s International Recognition Procedure
• Beckley Psytech Shares Topline Data from Phase 2a Study of 5-MeO-DMT for TRD
• Other News from Compass Pathways, Numinus, the UN Commission on Narcotic Drugs, and more.

Companies, organisations and drug candidates mentioned in this Bulletin: Lykos Therapeutics, MDMA-assisted therapy; Compass Pathways; COMP360; MHRA; Beckley Psytech; BPL-003; GH Research; GH001; Numinus; PharmAla Biotech; NIDA; MindBio.

This content is for Pα+ Subscribers

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.